Strategy and goals 2023-2026
Introduction
Oslo Cancer Cluster is a national, non-profit member organization with about 100 members. Our member base comprises university hospitals, research centres, patient organisations, start-ups, biotech companies, global pharma companies, technology companies, investors, financial institutions and service providers – all working in the cancer field. They cover the entire oncology value chain – from exploratory research to delivering novel therapeutics and diagnostics to patients worldwide.
We assume the following roles to fulfil the needs of our members:
- Facilitator: advancing a dynamic innovation ecosystem where companies, investors, academic researchers, clinicians and patients collaborate.
- Ambassador: connecting Norwegian innovators to global value chains, international investors and partners in academia and industry.
- Changemaker: improving the framework conditions for cancer innovations in the Norwegian health industry and raising expertise.
The board is responsible for Oslo Cancer Cluster’s strategy in collaboration with the cluster management. The board consists of 10 highly skilled and experienced member representatives covering the oncology value chain – from basic research to globally marketed products.
Our mission: Accelerate the development of innovative cancer treatments and diagnostics.
Our vision: Help patients by accelerating the development of innovative cancer treatments.
The strategy paves the path for Oslo Cancer Cluster’s mission: To accelerate the development of innovative cancer treatments and diagnostics, with the vision of helping patients.
The facilitator
Advancing a dynamic innovation ecosystem where companies, investors, academic researchers, clinicians, and patients collaborate.
We have:
- assisted more start-ups in succeeding.
- supported a growing incubator.
- promoted an expanding innovation park.
We will:
- become a preferred partner for the development of innovative cancer treatments.
- create collaborations with other mature clusters, which will increase the value of the Norwegian health industry.
- establish infrastructures for innovative cancer treatments in areas where Norway excels, such as cell therapy, radiopharmacology and health data.
The ambassador
Connecting Norwegian innovators to global value chains, international investors and partners in academia and industry.
We have:
- become a leading innovation ecosystem both in Norway and in the Nordics.
- strengthened Nordic collaboration in the cluster.
- helped member companies establish themselves internationally.
We will:
- connect members to international partners and leading cancer research environments.
- showcase international investment opportunities and companies present in Oslo Cancer Cluster Innovation Park.
- make Norway attractive for talents from all over the world by showing the possibilities in an internationally oriented cluster.
The changemaker
Improving the framework conditions for cancer innovations in the Norwegian health industry.
We have:
- strengthened the collaboration with Ullern Upper Secondary School.
- created new collaborations between public and private actors in precision medicine through the CONNECT consortium.
- enhanced the collaboration between health clusters on digitalisation and testing in co-creating the company Health Catalyst.
- made the health industry a more understandable opportunity for politicians in Norway.
- actively adapted facilities for vaccine development in Oslo Innovation Park.
We will:
- contribute to better framework conditions for a stronger Norwegian and European health industry, for instance by taking a clear role in international projects like Cancer Mission.
- achieve long term, predictable financing of an attractive cluster for better cancer treatment, for instance by showcasing mature clusters as triggering for innovation projects, value creation, and jobs.
- position both Oslo Cancer Cluster and Oslo Science City as key arenas for creating more jobs in the Oslo region.
- contribute to develop sustainable cancer vaccine production capabilities in Norway.
